Abstract:Background Integrins are the major adhesive molecules in mammalian cells. Each integrin subtype plays a unique role in cell differentiation and embryo development. However, integrin involvement in carcinogenesis has not been well defined. Methods We identified mutations in integrin alpha 7 by sequencing genomic DNAs and cDNAs from 122 specimens, including 62 primary human tumor samples, four cell lines, and 56 matched normal tissues. We evaluated the tumor suppressor activity of integrin alpha 7 with colony formation, soft agar colony growth, and cell migration assays by forcing its expression in PC-3 and Du145 prostate cancer cells and SK-UT-1 leiomyosarcoma cells. PC-3 and Du145 xenograft tumors with increased levels of integrin 0 in severe combined immune deficient mice were used to assess the effect of integrin alpha 7 on tumor growth and metastasis. Immunostaining was used to localize and to measure the level of integrin alpha 7 in 701 and 141 specimens of prostate and smooth muscle, respectively. A meta-analysis of integrin alpha 7 mRNA microarray data from four studies was performed. Kaplan-Meier analyses were used to assess survival. All statistical tests were two-sided. Results Integrin alpha 7 mutations that generate truncations were found in specimens of 16 of 28 prostate cancers (57%, 95% confidence interval [Cl] = 37% to 76%), five of 24 hepatocellular carcinomas (21%, 95% Cl = 7% to 42%), five of six glioblastomas multiforme (83%, 95% Cl = 36% to 99%), and one of four leiomyosarcomas (25%, 95% Cl = 0.6% to 81%). Integrin alpha 7 mutations were associated with increased recurrence of human prostate cancer (nine recurrences among 13 patients with integrin alpha 7 mutations versus one among eight without such mutations; odds ratio [OR] = 14, 95% Cl = 1.15 to 782, P =.024) and hepatocellular carcinoma (five recurrences among eight patients with integrin 0 mutations versus one among 16 without such mutations, OR = 21, 95% Cl = 1.6 to 1245; P =.007). Forced expression of normal integrin alpha 7 in prostate cancer and leiomyosarcoma cell lines suppressed tumor growth and metastasis both in vitro and in vivo. Focal or no integrin alpha 7 expression in human prostate cancer and soft tissue leiomyosarcoma was associated with a reduction of metastasis-free survival (for example, for prostate cancer with focal or no expression, 5-year metastasis-free survival was 32%, 95% Cl = 24.4% to 46.3%, and for prostate cancer with at least weak expression, it was 85%, 95% Cl = 79% to 91%; P<.001). Microarray analysis indicated that cyclin D kinase inhibitor 3 and GTPase-activating protein may be possible targets for integrin alpha 7-mediated tumor suppressor activity and inhibition of cell motility. Conclusion Integrin alpha 7 appears to be a tumor suppressor that operates by suppressing tumor growth and retarding migration.

Mutations in the Integrin Α7 Gene Cause Congenital Myopathy

Compound heterozygous mutations in TTC7A cause familial multiple intestinal atresias and severe combined immunodeficiency.

Characteristics of the beta myosin heavy chain gene Ala26Val mutation in a Chinese family with hypertrophic cardiomyopathy.

Case Report: A Boy From a Consanguineous Family Diagnosed With Congenital Muscular Dystrophy Caused by Integrin Alpha 7 (ITGA7) Mutation

A Novel MYH7 Mutation Resulting in Laing Distal Myopathy in a Chinese Family

A Genetic Defect in Muscle Phosphofructokinase Deficiency, a Typical Clinical Entity Presenting Myogenic Hyperuricemia.

A mutation in DOK7 in congenital myasthenic syndrome forms aggresome in cultured cells, and reduces DOK7 expression and MuSK phosphorylation in patient-derived iPS cells

Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor epsilon subunit gene: identification and functional characterization of six new mutations

Mutation analysis of LITAF, RAB7, LMNA and MTMR2 genes in Chinese Charcot-Marie-Tooth disease.]

Bi-allelic mutations in MYL1 cause a severe congenital myopathy

A spontaneous missense mutation in the chromodomain helicase DNA-binding protein 8 (CHD8) gene: a novel association with congenital myasthenic syndrome

Recessive Mutations in Proximal I-band of TTN Gene Cause Severe Congenital Multi-Minicore Disease Without Cardiac Involvement

Mutations in the satellite cell gene MEGF10 cause a recessive congenital myopathy with minicores

Genetic analysis of a family affected by congenital myasthenic syndrome due to a Novel mutation in the SLC5A7 gene

Novel TUBA4A variant causes congenital myopathy with focal myofibrillar disorganisation

Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma.

Molecular mechanisms linking missense ACTG2 mutations to visceral myopathy

Genetic defect in muscle phosphofructokinase deficiency. Abnormal splicing of the muscle phosphofructokinase gene due to a point mutation at the 5'-splice site.

A Novel Recessive Mutation Affecting DNAJB6a Causes Myofibrillar Myopathy

A Novel Alpha Cardiac Actin (ACTC1) Mutation Mapping to a Domain in Close Contact with Myosin Heavy Chain Leads to a Variety of Congenital Heart Defects, Arrhythmia and Possibly Midline Defects

Study of a Bethlem Myopathy Pedigree Resulted from a Novel Mutation of COL6A3 Gene